28 Sep 2026, 08:45 IST
Emcure Pharmaceuticals Limited
Motilal Oswal Financial Services Ltd. · Buy · target 2,300
The report lists Emcure Pharma as a focus investment idea with a Buy rating and 17% upside target.
From MOStMarketOutlook28092026, written by Motilal Oswal Financial Services Ltd. and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd.'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.